ProCE Banner Activity

Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma

Slideset Download
Conference Coverage
At a median follow-up of 3.5 years, rituximab plus lenalidomide demonstrated durable CR/CRu and prolonged PFS vs rituximab alone in previously untreated in follicular lymphoma.

Released: December 09, 2016

Expiration: December 08, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen